Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human anti-rabies virus monoclonal antibody
- Development stage
- Phase 2
- Lead developer
- Lanzhou Institute of Biological Products
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Recombinant human anti-rabies virus monoclonal antibody is a biological drug developed by the Lanzhou Institute of Biological Products, a subsidiary of China National Biotec Group (Sinopharm), for the post-exposure prophylaxis (PEP) of rabies. This monoclonal antibody is designed to provide immediate passive immunity by specifically binding to and neutralizing the rabies virus glycoprotein (G protein), thereby preventing the virus from attaching to and entering host cells at the site of exposure. It is intended to be used in combination with the rabies vaccine, serving as a more standardized and potentially safer alternative to traditional blood-derived products like human rabies immunoglobulin (HRIG) or equine rabies immunoglobulin (ERIG). The drug is currently in Phase 3 clinical trials in China, where it is being evaluated for its safety, immunogenicity, and efficacy in individuals exposed to the rabies virus.
- Other names
- 重组人抗狂犬病病毒单克隆抗体Rabies monoclonal antibodyHuman anti-rabies virus monoclonal antibody
02
Targets
RABV-G site III (Rabies virus glycoprotein antigenic site III)
Beyond the preview
Go deeper on recombinant human anti-rabies virus monoclonal antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human anti-rabies virus monoclonal antibody.